Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketotifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketotifen SCHEMBL8809 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL8810 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1170677 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL226911 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL27443523 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL27685749 | 0.99 | DRD3 (0.98) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL28259804 | 0.99 | DRD3 (0.98) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL9060252 | 0.92 | DRD3 (0.89) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL4436 | 0.91 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL29356083 | 0.91 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037107-A2 | LASER | SKYLARK LASERS LTD (GB) | 2025-02-20 | — | — | WO | claimed |
| EP-3416617-B1 | COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINERGIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN | DAMBROSIO ENZO MARIA (IT) | 2024-12-18 | — | — | EP | claimed |
| EP-3357945-B1 | ADHESIVE POLYMER AND MEDICAL ADHESIVE PATCH | TEIKOKU SEIYAKU KK (JP) | 2024-10-30 | — | — | EP | claimed |
| EP-3210594-B1 | METHODS AND OPHTHALMIC DEVICES USED IN THE TREATMENT OF OCULAR ALLERGIES | JOHNSON & JOHNSON VISION CARE (US) | 2023-09-13 | — | — | EP | claimed |
| US-11515572-B2 | Molecular crowding type electrolyte and battery comprising the same | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2022-11-29 | — | — | US | claimed |
| EP-2437684-B1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5 INC (US) | 2022-06-15 | — | — | EP | claimed |
| EP-4212495-B1 | PARAMAGNETIC GARNET-BASED TRANSPARENT CERAMIC AND METHOD FOR PRODUCING THE SAME | SHINETSU CHEMICAL CO (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12594251-B2 | Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19 | BAUSCH + LOMB IRELAND LIMITED (IE) | 2026-04-07 | — | — | US | disclosed |
| WO-2026042047-A1 | COMPOSITIONS AND ARTICLES COMPRISING REVERSIBLE COMPLEXES OF CROSSLINKED CARRAGEENAN | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4662528-A1 | POLARIZATION ROTATION DEVICE AND FARADAY ISOLATOR | Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-12490932-B2 | Ophthalmic drug delivery | EYENOVIA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250328033-A1 | COMPACT POLARIZATION-DEPENDENT FARADAY ISOLATOR | ELECTRO-OPTICS TECHNOLOGY, INCORPORATED (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | Sydnexis, Inc. | 2025-09-04 | — | — | US | disclosed |
| CN-115038414-A | System and device for delivering fluid to an eye and method of use | 艾诺维亚股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11428914-B1 | Small, high power optical isolator | ELECTRO-OPTICS TECHNOLOGY, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11398306-B2 | Ophthalmic drug delivery | EYENOVIA, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220192975-A1 | BOUNDARY SURFACE CHARGED CONTACT LENS FOR DELIVERY | LYNTHERA CORPORATION | 2022-06-23 | — | — | US | disclosed |
| WO-2022126100-A1 | BOUNDARY SURFACE CHARGED CONTACT LENS FOR DELIVERY | LYNTHERA CORPORATION (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022079664-A1 | BENZALKONIUM CHLORIDE FOR USE IN TREATING CONJUNCTIVITIS AND/OR COVID-19 | Bausch & Lomb Ireland Limited (IE) | 2022-04-21 | — | — | WO | disclosed |
| US-20220062035-A1 | SPRAY EJECTOR MECHANISMS AND DEVICES PROVIDING CHARGE ISOLATION AND CONTROLLABLE DROPLET CHARGE, AND LOW DOSAGE VOLUME OPHTHALMIC ADMINISTRATION | HYPERION DEFI, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | AQP1, AQP3, CRYZ | HRH1 11/4885DRD3 429/4885CHRM2 1748/4885 |
| US-20220192975-A1 | BOUNDARY SURFACE CHARGED CONTACT LENS FOR DELIVERY | CRYZ, CRYAA, CLCN2 | HRH1 1971/4885DRD3 3357/4885CHRM2 351/4885 |
| US-12594251-B2 | Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19 | CLIC1, CLCN2, CLIC4 | HRH1 135/4885DRD3 988/4885CHRM2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.